[Natural killer activity in respiratory papillomatosis and its changes after interferon treatment]. 1991

A D Pritsker, and S S Grigorian, and E K Onufrieva, and D G Chireshkin, and F I Ershov

A method to determine changes in the activity of natural killers (NK) in treatment of juvenile respiratory papillomatosis in children and correlation with the clinical course of the disease was developed and studies with whole blood specimens were carried out before interferon (IF) treatment and after it. Initially high levels of NK activity and their subsequent decline were observed in the cases where IF treatment had no effect, whereas initially low levels with subsequent increase after treatment or normal levels remaining unchanged in the course of treatment were typical of the patients manifesting some clinical effect of the treatment. These studies confirm the possibility of the modulating effect of IF, and the method may be used in mass surveys and working with children.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D010212 Papilloma A circumscribed benign epithelial tumor projecting from the surrounding surface; more precisely, a benign epithelial neoplasm consisting of villous or arborescent outgrowths of fibrovascular stroma covered by neoplastic cells. (Stedman, 25th ed) Papilloma, Squamous Cell,Papillomatosis,Papillomas,Papillomas, Squamous Cell,Papillomatoses,Squamous Cell Papilloma,Squamous Cell Papillomas
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D012142 Respiratory Tract Neoplasms Tumors or cancer of the RESPIRATORY SYSTEM. Respiratory Neoplasms,Respiratory System Neoplasms,Neoplasm, Respiratory,Neoplasm, Respiratory System,Neoplasm, Respiratory Tract,Respiratory Neoplasm,Respiratory System Neoplasm,Respiratory Tract Neoplasm
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003601 Cytotoxicity Tests, Immunologic The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitized lymphocyte, an antibody, or complement. AHG-CDC Tests,Anti-Human Globulin Complement-Dependent Cytotoxicity Tests,Microcytotoxicity Tests,Anti Human Globulin Complement Dependent Cytotoxicity Tests,Anti-Human Globulin Complement-Dependent Cytotoxicity Test,Antiglobulin-Augmented Lymphocytotoxicity Test,Antiglobulin-Augmented Lymphocytotoxicity Tests,Cytotoxicity Test, Immunologic,Cytotoxicity Tests, Anti-Human Globulin Complement-Dependent,Cytotoxicity Tests, Immunological,Immunologic Cytotoxicity Test,Immunologic Cytotoxicity Tests,Lymphocytotoxicity Test, Antiglobulin-Augmented,Lymphocytotoxicity Tests, Antiglobulin-Augmented,Microcytotoxicity Test,AHG CDC Tests,AHG-CDC Test,Anti Human Globulin Complement Dependent Cytotoxicity Test,Antiglobulin Augmented Lymphocytotoxicity Test,Antiglobulin Augmented Lymphocytotoxicity Tests,Cytotoxicity Test, Immunological,Cytotoxicity Tests, Anti Human Globulin Complement Dependent,Immunological Cytotoxicity Test,Immunological Cytotoxicity Tests,Lymphocytotoxicity Test, Antiglobulin Augmented,Lymphocytotoxicity Tests, Antiglobulin Augmented
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500

Related Publications

A D Pritsker, and S S Grigorian, and E K Onufrieva, and D G Chireshkin, and F I Ershov
October 1982, Clinical immunology and immunopathology,
A D Pritsker, and S S Grigorian, and E K Onufrieva, and D G Chireshkin, and F I Ershov
January 1984, The Annals of otology, rhinology, and laryngology,
A D Pritsker, and S S Grigorian, and E K Onufrieva, and D G Chireshkin, and F I Ershov
October 1984, Ear, nose, & throat journal,
A D Pritsker, and S S Grigorian, and E K Onufrieva, and D G Chireshkin, and F I Ershov
June 1981, Immunobiology,
A D Pritsker, and S S Grigorian, and E K Onufrieva, and D G Chireshkin, and F I Ershov
December 2021, Journal of surgical oncology,
A D Pritsker, and S S Grigorian, and E K Onufrieva, and D G Chireshkin, and F I Ershov
December 1994, Biulleten' eksperimental'noi biologii i meditsiny,
A D Pritsker, and S S Grigorian, and E K Onufrieva, and D G Chireshkin, and F I Ershov
January 1980, Annals of the New York Academy of Sciences,
A D Pritsker, and S S Grigorian, and E K Onufrieva, and D G Chireshkin, and F I Ershov
March 1998, Journal of neuroimmunology,
A D Pritsker, and S S Grigorian, and E K Onufrieva, and D G Chireshkin, and F I Ershov
August 1982, International journal of cancer,
A D Pritsker, and S S Grigorian, and E K Onufrieva, and D G Chireshkin, and F I Ershov
March 1983, Biochemical and biophysical research communications,
Copied contents to your clipboard!